Seaport Therapeutics, a Phase 2 biotech developing therapies for neuropsychiatric indications, announced terms for its IPO on Monday. The Boston, MA-based company plans to raise $201 million by offering 11.8 million shares at a price range of $16 to $18....read more
Updated Monday, 4/27. A handful of IPOs are currently scheduled for the week ahead, joined by Bill Ackman’s Pershing Square deals. Some smaller issuers may also join the calendar throughout the week. Neuropsychiatric therapeutics biotech ...read more
One IPO priced this past week, joined by two SPACs, and twelve deals joined the pipeline. Canadian royalty acquirer The Metals Royalty Co. (TMCR) completed its direct listing on the Nasdaq and opened for trading at $15, where it commanded a market cap of...read more
Seaport Therapeutics, a Phase 2 biotech developing therapies for neuropsychiatric indications, filed on Friday with the SEC to raise up to $100 million in an initial public offering. Seaport Therapeutics is a clinical-stage biotechnology company developing...read more
Neuropsychiatric therapeutics Seaport Therapeutics sets terms for $201 million IPO, pricing this week
Seaport Therapeutics, a Phase 2 biotech developing therapies for neuropsychiatric indications, announced terms for its IPO on Monday. The Boston, MA-based company plans to raise $201 million by offering 11.8 million shares at a price range of $16 to $18....read more
US IPO Week Ahead: Biotechs, mining, and Bill Ackman deals set to debut
Updated Monday, 4/27. A handful of IPOs are currently scheduled for the week ahead, joined by Bill Ackman’s Pershing Square deals. Some smaller issuers may also join the calendar throughout the week. Neuropsychiatric therapeutics biotech ...read more
US IPO Weekly Recap: Pipeline swells with sizable IPO filings as Metals Royalty direct lists
One IPO priced this past week, joined by two SPACs, and twelve deals joined the pipeline. Canadian royalty acquirer The Metals Royalty Co. (TMCR) completed its direct listing on the Nasdaq and opened for trading at $15, where it commanded a market cap of...read more
Neuropsychiatric therapeutics biotech Seaport Therapeutics files for a $100 million IPO
Seaport Therapeutics, a Phase 2 biotech developing therapies for neuropsychiatric indications, filed on Friday with the SEC to raise up to $100 million in an initial public offering. Seaport Therapeutics is a clinical-stage biotechnology company developing...read more